IP Library Granted Patent US 8,399,425
Granted Patent B2
US 8,399,425 · App. 12/741,016 · Granted Mar 19, 2013

Alleviating neuropathic pain with EETs and sEH inhibitors

Inventors: Bruce D. Hammock (Davis, CA); Ahmet Bora Inceoglu (Davis, CA); Steven L. Jinks (Davis, CA)
Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,399,425
App. No.
12/741,016
Granted
Mar 19, 2013
Kind
B2
Abstract

The invention discloses methods of using cis-epoxyeicosantrienoic acids (“EETs”), inhibitors of soluble epoxide hydrolase (“sEH”), or a combination of an EET and an inhibitor of sEH, to alleviate neuropathic pain in subjects suffering from such pain.

Claims (15)

1. A method of relieving neuropathic pain in a subject in need thereof, said method comprising administering to said subject an effective amount of an agent or agents selected from the group consisting of a cis-epoxyeicosantrienoic acid (“EET”), an inhibitor of soluble epoxide hydrolase (“sEH”), and a combination of an EET and an inhibitor of sEH, thereby relieving said neuropathic pain in said subject.

2. A method of claim 1 , wherein the agent is an EET.

3. A method of claim 1 , wherein the EET is selected from the group consisting of 14,15-EET, 8,9-EET, 11,12-EET or 5,6-EET.

4. A method of claim 1 , wherein the EET is synthetic or an EET analog.

5. A method of claim 1 , wherein the agent is an inhibitor of sEH.

6. A method of claim 1 , wherein the agent is administered orally.

7. A method of claim 1 , wherein the agent is administered intravenously.

8. A method of claim 1 , wherein the agent is administered intrathecally.

9. A method of claim 1 , wherein the neuropathic pain is central neuropathic pain.

10. A method of claim 1 , wherein the neuropathic pain is peripheral neuropathic pain.

11. A method of claim 1 , wherein the neuropathic pain is selected from the group consisting of post-herpetic neuralgia, trigeminal neuralgia, focal peripheral nerve injury, and anesthesia dolorosa, central pain due to stroke or mass lesion, spinal cord injury, or multiple sclerosis, and peripheral neuropathy due to diabetes, HIV, or chemotherapy.

12. A method of claim 1 , wherein the subject is experiencing neuropathic pain at the time of administration.

13. A method of claim 1 , wherein the inhibitor of sEH comprises a pharmacophore comprising a urea, a carbamate, or an amide.

14. A method of claim 1 , wherein the inhibitor of sEH comprises an IC 50 of less than about 500 μM

15. A method of claim 1 , wherein the inhibitor of sEH comprises an IC 50 of less than about 1 μM

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 1, 2011
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026535/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2010
From: HAMMOCK, BRUCE D.; INCEOGLU, AHMET BORA; JINKS, STEVEN L.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 024514/0856 →
Continuity (2)
Provisional Application 60986560 · Nov 8, 2007
Related Publication 20100267807A1 · Oct 21, 2010